VuCOMP

VuCOMP develops advanced imaging software utilizing artificial intelligence to enhance cancer detection capabilities, especially in mammography and breast health, aiming to improve diagnostic accuracy and patient outcomes. VuCOMP was founded in 2001 and is headquartered in Plano, Texas, US. The company specializes in imaging solutions for cancer detection. In January 2016, VuCOMP was acquired by iCAD, with financial terms not disclosed.

The company has completed a total of 6 deals to date. VuCOMP specializes in artificial intelligence-powered solutions for cancer detection, focusing on breast health. Their primary offerings include ProFound AI Detection, which enhances mammography readings by identifying cancers earlier and reducing recall rates, the PowerLook Density Assessment for evaluating breast density, and the ProFound AI Risk model, which significantly outperforms traditional risk assessment models. These products streamline workflows for healthcare providers while improving patient outcomes, serving diagnostic imaging centers, hospitals, and radiology practices globally.

VuCOMP's revenue is generated through the sale and licensing of its AI-driven products and services. They engage in B2B transactions with healthcare institutions, providing solutions integrated into existing workflows. Revenue derives from direct sales of their flagship products, including ProFound AI Detection and PowerLook Density Assessment, and subscription models for updates and support services. VuCOMP plans to leverage its recent acquisition by iCAD to enhance its product offerings and expand into new markets.

The company is focusing on rolling out improved versions of its AI detection technologies, although specific launch dates are not detailed. Funding raised in the latest round will support these initiatives and facilitate market expansion efforts in regions yet to be specified. The most recent deal was concluded on January 13, 2016.